Company intelligence / Profile preview

DroobiSmit

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

DroobiSmit’s platform has demonstrated significant clinical outcomes in real-world settings. Among high-risk users, 85% saw a reduction in blood sugar levels (average HbA1c decrease of 2.5%), 80% achieved at least 5% weight loss, and over one-third reduced medication dependence within three months. The company reports transforming the lives of over 40,000 users to date.

Therapeutic areas: Metabolic DisordersEndocrinologyCardiovascular
Modalities: Digital therapeuticAI-powered digital twin technologyPersonalized coaching
Industry: Digital Health Medical Devices

Partnerships

Over 25 leading healthcare players across GCC and India including top-tier hospitals, clinic chains, insurance companies, employersgovernment agenciespharmaceutical/device companies for patient support programs

Beyond the preview

Go deeper on DroobiSmit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DroobiSmit.

Explore the full profile